8
Participants
Start Date
March 7, 2018
Primary Completion Date
November 12, 2019
Study Completion Date
December 4, 2019
EB8018 (First-in-class FimH blocker)
"Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker~• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13."
Medical University Vienna, Vienna
Hôpital Claude Huriez, Lille
Hôpital de l'Archet 2, Nice
Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel
Istituto Clinico Humanitas, Rozzano
Lead Sponsor
Enterome
INDUSTRY